Beijing, China
Annoroad Genomics is the leading developer and marketer of genomic innovation technologies for research and clinical markets in China. Founded in 2012 and headquartered in Beijing, the company operates a top throughput NGS sequencing center and cloud-based bioinformatics platform. Annoroad offers services and products to customers in hospitals and research organizations. The company recently secured a CNY700.00M Series C investment on 03 November 2017 from prominent investors including SBCVC, Ping An Ventures, SAIF Partners, and ShenZhen GTJA Investment Group.
Annoroad's focus on biotechnology and healthcare industries positions it at the forefront of genomic innovation in China. The recent substantial investment is a testament to investor confidence in the company's potential for growth and impact in the genomics market. With its cutting-edge technologies and strategic partnerships, Annoroad is well-positioned to capitalize on the growing demand for genomic research and clinical applications in China.
Investors should closely monitor Annoroad's progress and market expansion, as the company continues to strengthen its position as a key player in the genomics industry. The recent Series C investment signifies a significant milestone for Annoroad's growth trajectory, making it a compelling prospect for venture capital firms seeking opportunities in the biotechnology and healthcare sectors within China's burgeoning innovation ecosystem.
